Document:

<PAGE>

          CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED
          AND FILED SEPARATELY WITH THE COMMISSION, CONFIDENTIAL TREATMENT
          HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                                                                 EXHIBIT 10.19

                    DRUGABUSE SCIENCES, INC. SUPPLY AGREEMENT

         This Supply Agreement is made and entered into effective on and as of
June 9, 2000 by and between the Pharmaceutical Group of Mallinckrodt Inc.
("Mallinckrodt") and DrugAbuse Sciences ("DAS").

         WHEREAS, DAS has need of a certain compound known as Naltrexone Base
Anhydrous (hereinafter "Product") and is desirous of having Product
manufactured and supplied by Mallinckrodt on the conditions set forth herein;
and

         WHEREAS, Mallinckrodt currently manufactures and markets Product and is
capable and desirous of undertaking the supply of Product for DAS in accordance
with the terms and conditions set forth herein;

         NOW, THEREFORE, in consideration of the promises, covenants and
representations of the parties set forth herein, and other good and sufficient
consideration receipt of which is hereby acknowledged, DAS and Mallinckrodt
agree as follows:

         1.   SUPPLY OF PRODUCT.

              (a)  For the consideration provided herein and in accordance
                   with all terms, conditions, representations and warranties
                   set forth herein, and for the term hereof, Mallinckrodt
                   will provide DAS with such amounts of Product as DAS shall
                   request. DAS agrees that it shall purchase at least
                   [******] of its requirements for Product from Mallinckrodt
                   hereunder during every Contract Year during the term of
                   this Agreement. For purposes of the preceding sentence
                   "Contract Year" shall mean (i) for the first year of this
                   Agreement, the period beginning on June 9, 2000 and ending
                   on June 30, 2001, and (ii) for each year thereafter during
                   the term of this Agreement, the twelve (12) month period
                   beginning on July 1 and ending on June 30. All Product
                   supplied hereunder shall be manufactured by Mallinckrodt
                   strictly in accordance with the Specifications (defined
                   below) and current Good Manufacturing Practices ("cGMP")
                   as determined by the United States Food and Drug
                   Administration ("FDA") using the manufacturing process
                   described in Mallinckrodt's Drug Master File. If and as
                   applicable, Mallinckrodt shall comply with the cGMP of
                   those countries outside the United States represented on
                   Exhibit B.

              (b)  The specifications for Product (including, without
                   limitation, specifications for all components and raw
                   materials, whether active or inactive) are described on
                   Exhibit A attached hereto ("Specifications").

              (c)  Notwithstanding anything to the contrary herein and if,
                   for any Contract Year after the first Contract Year of
                   this Agreement, Mallinckrodt is unable to supply DAS with
                   such quantities of Product as DAS shall order hereunder,
                   the minimum amount of Product that Mallinckrodt shall be
                   obligated to supply to DAS in any given Contract Year
                   thereafter, shall be that amount of Product ordered by DAS
                   in any such subsequent Contract Year which represents the
                   [******] sold by Mallinckrodt to all unaffiliated parties
                   and to other Mallinckrodt business

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION, CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.
<PAGE>

          CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED
          AND FILED SEPARATELY WITH THE COMMISSION, CONFIDENTIAL TREATMENT
          HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

              units in such subsequent Contract Year as the [******] in the
              immediately previous Contract Year bears to the [******] of all
              forms of [******] to all [******] and to [******] business
              units in such immediately previous Contract Year.

    2.   RAW MATERIALS.

         Subject to the provisions of Section 4 below, all raw materials and
         other resources required in connection with the production of Product
         to be supplied hereunder shall be provided by Mallinckrodt [******].

    3.   QUALITY CONTROL.

         (a)  Mallinckrodt will take all steps reasonably necessary to ensure
              that it has the facilities, equipment, instrumentation, resources
              and trained personnel to provide all raw materials, in-process and
              product assays, analysis and other testing (including preparing,
              submitting and maintaining a foreign Drug Master File for Product
              if required by DAS), as compliance with cGMP standards, other FDA
              standards, or the standards of the regulatory agencies of European
              countries listed in Exhibit B may require in connection with
              Mallinckrodt's supply of Product. Mallinckrodt shall provide a
              complete certificate of analysis for each lot of Product supplied
              hereunder at the time of shipment.

         (b)  Mallinckrodt shall maintain complete and accurate documentation of
              all validation data, stability testing data, batch records,
              quality control and laboratory testing and any other data required
              under cGMP or other FDA requirements or the requirements of the
              regulatory agencies of European countries listed in Exhibit B in
              connection with the supply of Product hereunder.

         (c)  Mallinckrodt warrants that it will not engage in any act which
              causes any packaged and labeled Product produced by Mallinckrodt
              to become adulterated or misbranded, and agrees that such Product
              will not be adulterated or misbranded, within the meaning of the
              federal Food, Drug and Cosmetic Act, as amended, when Product is
              delivered to DAS.

         (d)  Mallinckrodt agrees to inform DAS of any significant changes
              related to the Product Drug Master File ("DMF") that would
              required a NDA supplement from DAS, and Mallinckrodt agrees to
              continue to supply unmodified Product to DAS as ordered under the
              terms of and subject to the conditions and limitations of this
              Agreement for a maximum of two (2) years after DAS is informed in
              writing of the new DMF change filing with all applicable
              regulatory agencies.

    4.   COMPENSATION SERVICES PERFORMED BY MALLINCKRODT.

         (a)  For each kilogram of Product supplied hereunder produced in
              accordance with the requirements hereof, DAS shall pay
              Mallinckrodt, for Product to

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION, CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                        2
<PAGE>

          CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED
          AND FILED SEPARATELY WITH THE COMMISSION, CONFIDENTIAL TREATMENT
          HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

              be produced and delivered in any particular Contract Year during
              the term hereof; as follows (the "Product Price"):

              (i)   [******]

              (ii)  [******] and

              (iii) [******]; for the sake of clarity, this means that if, for
                    example, [******]

              The Product Price set forth in the immediately preceding
              sentence shall be firm through the first Contract Year ending
              on June 30, 2001, the date of June 30 (since it is the end of
              every Contract Year during the term hereof) being hereinafter
              referred to as the "Adjustment Date." From and after the
              Adjustment Date, the Product Price shall be adjusted upward or
              downward (as the case may be) to reflect actual increases or
              decreases in the cost to Mallinckrodt of all raw materials,
              directly associated regulatory compliance costs and all
              directly allocated labor (all of which costs are hereinafter
              referred to at "Product Costs"), in accordance with the
              following procedures; provided, however, that if the Product
              Price increases in any year by more than [******] Mallinckrodt
              agrees that DAS can hire, at its own expense, an independent
              third party to audit Mallinckrodt's books and records to
              determine whether Mallinckrodt's increase in the Product Price
              complies with the terms of this Agreement. Within [******]
              prior to the end of each Contract Year hereunder during the
              term hereof, Mallinckrodt will notify DAS in writing of the
              amount by which its Product Costs hereunder have increased or
              decreased during the immediately preceding Contract Year period
              and the adjusted Product Price to be charged for the Contract
              Year [******] just commenced as a consequence of such increases
              or decreases ("Annual Adjustment Notice"). The amount of any
              increase or decrease in the Product Price as set forth in any
              Annual Adjustment Notice shall be effective for all Product
              invoiced by Mallinckrodt to DAS in accordance herewith during
              the Contract Year for which such Annual Adjustment Notice is
              issued.

         (b)  At the time of shipment by Mallinckrodt to DAS of any lot of
              Product hereunder, Mallinckrodt shall submit to DAS an invoice
              setting forth the total amount of Product being shipped to DAS and
              the amount due to Mallinckrodt under subscate of analysis and a
              certification that the Product for which DAS is being billed has
              been produced fully in conformance with applicable Specifications,
              cGMP and the requirements hereof. Any such invoice shall be
              payable by DAS in United States dollars [******].

    5.   FORECASTS, ORDER PLACEMENT AND DELIVERY.

         (a)  Three (3) months prior to anticipated manufacture of Product,
              Mallinckrodt will notify DAS in writing of the anticipated
              manufacture date. No less than [******] prior to the
              anticipated manufacture date that has been provided by
              Mallinckrodt to DAS in accordance with the preceding sentence,
              [******] (in accordance with the requirements and procedures
              hereof) all Product required by DAS for the [******] following
              such anticipated manufacture date. DAS may specify that Product
              shall be delivered monthly along with the amounts to be so
              delivered, or according to any reasonable alternative schedule,
              and Mallinckrodt shall deliver Product according to such
              schedule and in the quantities specified.

         (b)  Product shall be ordered by DAS only in writing. Mallinckrodt will
              not accept verbal orders of any kind for the production of
              Product. Any written work order will contain the following
              information: (i) the precise quantity of Product desired and
              required delivery dates (consistent with subsection (a) set forth
              immediately above), (ii) the anticipated shipping destination for
              Product and (iii) such other information as DAS wishes to

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION, CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       3
<PAGE>

              provide or that Mallinckrodt might find necessary or useful in
              completing a specific work order.

         (c)  Product shall be delivered F.O.B. North American shipping
              destination (with the specific destination to be determined by
              DAS), freight prepaid by Mallinckrodt, no earlier than three (3)
              days prior to the requested delivery date, and no later than the
              delivery date. Mallinckrodt will be responsible to make such
              arrangements regarding the shipping of Product to designated
              destinations as DAS shall reasonably request.

    6.   ACCEPTANCE AND REJECTIONS AND RECALLS.

         (a)  If DAS reasonably determines that any Product is defective in
              material or workmanship, not in conformance with applicable
              Specifications, is adulterated or misbranded, or is otherwise not
              in conformity with this Supply Agreement (Product meeting any or
              all of such circumstances hereinafter referred to as a "Defective
              Product"), then (DAS), in addition to any other rights it may have
              under this Supply Agreement, may reject and return any such
              Products to Mallinckrodt. At the time of any such rejection, DAS
              shall provide Mallinckrodt with a written notice describing in
              detail the circumstances surrounding the rejection and DAS'
              reasons therefor. If DAS rejects any such Products it will, at
              Mallinckrodt's option, either return them to Mallinckrodt or
              destroy or dispose of them in the least expensive and most
              environmentally sound manner. In any event, Mallinckrodt shall be
              responsible for the costs of any such return, destruction or
              disposal. It is understood that DAS' sole remedies hereunder in
              the event of a Defective Product it has rejected will either be
              (i) the replacement by Mallinckrodt of rejected Products that have
              either been returned or destroyed with Products that are not
              Defective Products or (ii) a full refund of any amount paid
              hereunder by DAS for such Defective Products, including all
              reasonable transportation and testing costs.

         (b)  Any Product received by DAS from Mallinckrodt that has not been
              rejected by DAS within sixty (60) days after receipt shall be
              deemed to have been accepted, except where such Product contains a
              nonconformity that was not discovered by DAS after reasonable
              inspection, in which case DAS shall have an additional sixty (60)
              days after it discovers such nonconformity within which to reject
              such Product according to the procedures set forth in Section 6(a)
              above.

         (c)  If DAS reasonably decides to or is required to initiate a product
              recall, withdrawal or field correction with respect to, or if
              there is any governmental seizure of, its products containing any
              Product supplied hereunder which action is due, in whole or in
              part, to (i) a failure of any of the Product manufactured by
              Mallinckrodt hereunder to conform to applicable Specifications
              (including, without limitation, it being

                                       4
<PAGE>

              adulterated or misbranded), or any warranty or other requirement
              set forth in this Supply Agreement, (ii) the failure by
              Mallinckrodt to comply in all material respects with any
              applicable law, rule, regulation, standard, court order or decree
              or (iii) the negligent or intentional wrongful act or omission of
              Mallinckrodt in connection with the production of Product
              hereunder, DAS will notify Mallinckrodt promptly of the details
              regarding such action, including providing copies of all relevant
              documentation concerning such action. Mallinckrodt will fully
              cooperate with and use diligent efforts to assist DAS in
              investigating any such situation. All regulatory contacts that are
              made and all activities concerning seizure, recall, withdrawal or
              field correction will be coordinated by DAS and Mallinckrodt. The
              costs of the same shall be apportioned as set forth below.

         (d)  If any such recall, withdrawal, field correction or seizure occurs
              due solely to (i) a failure of any Product sold by Mallinckrodt
              hereunder to conform to applicable Specifications (including,
              without limitation, it being adulterated or misbranded) or any
              warranty or other requirement set forth in this Supply Agreement,
              (ii) the failure by Mallinckrodt to comply in all material
              respects with any applicable law, rule, regulation, standard,
              court order or decree or (iii) the negligent or intentional
              wrongful act or omission of Mallinckrodt in connection with the
              production of Product hereunder, then Mallinckrodt shall bear the
              full cost and expense of any such seizure, recall, withdrawal or
              field correction. If any such recall, withdrawal, field correction
              or seizure occurs due solely to (i) any pharmaceutical product
              manufactured, sold or distributed by DAS that contains Product
              failing to conform to its applicable specifications (including,
              without limitation, it being adulterated or misbranded) or
              otherwise being defective, (ii) the failure of DAS to comply in
              all material respects with any applicable law, rule, regulation,
              standard, court order or decree or (iii) the negligent or
              intentional wrongful act or omission of DAS, then DAS shall bear
              the full cost and expense of any such seizure, recall, withdrawal
              or field correction, If both Mallinckrodt and DAS contribute to
              the cause of a seizure, recall, withdrawal or field correction,
              the cost and expenses thereof will be shared in proportion to each
              party's contribution to the problem.

    7.   REGULATORY COMPLIANCE.

         (a)  Mallinckrodt will comply in all material respects with all
              federal, state and local laws, regulations and standards
              applicable to production by Mallinckrodt and its performance of
              its obligations hereunder, and will also use best efforts to
              comply with any applicable laws, regulations and standards of
              those European countries set forth on Exhibit B.

         (b)  Mallinckrodt will promptly furnish DAS with pertinent portions of
              all FDA (or other applicable regulatory authority) inspection
              reports and

                                       5
<PAGE>

              related correspondence directly related to and affecting its
              performance hereunder as and when such reports and correspondence
              become available to Mallinckrodt.

         (c)  Mallinckrodt will notify DAS immediately upon receipt of, and
              promptly provide DAS a copy of, the relevant portions of any
              warning (including any FDA Form 483), citation, notice,
              indictment, claim, lawsuit or proceeding issued or instituted by
              any federal, foreign, state or local governmental entity or agency
              against Mallinckrodt or any of its affiliates or of any revocation
              of any license or permit issued to Mallinckrodt or any of its
              affiliates, to the extent that any such occurrence relates to
              Mallinckrodt's performance hereunder.

    8.   CERTAIN REPRESENTATIONS AND WARRANTIES OF MALLINCKRODT.

         (a)  Mallinckrodt represents and warrants that all Product sold
              hereunder will (i) be produced in full compliance with cGMPs
              applicable to the Product, and (ii) will meet all Specifications,
              and (iii) will have a minimum shelf-life of twenty-four (24)
              months after the date of delivery to DAS (i.e., that Product
              during the entire shelf-life will comply with the Specifications).
              Upon request from DAS, Mallinckrodt will provide to DAS all data
              it has collected concerning the shelf-life of the Product beyond
              the twenty-four (24) month period referenced above.

         (b)  Mallinckrodt represents and warrants that there is no claim, suit,
              proceeding or investigation pending or, to the knowledge of
              Mallinckrodt, threatened against Mallinckrodt or any of its
              affiliates which might prevent or interfere with Mallinckrodt's
              performance under this Supply Agreement.

         (c)  Mallinckrodt represents and warrants to DAS that Product sold
              hereunder by Mallinckrodt will not be:

              (i)   in violation of Sections 5 or 12 of the Federal Trade
                    Commission Act or improperly labeled under applicable
                    Federal Trade Commission Trade Practice Rules, or other
                    similar European laws (for the countries set forth on
                    Exhibit B), as and to the extent applicable hereunder,

              (ii)  adulterated or misbranded within the meaning of the federal
                    Food, Drug and Cosmetic Act, as amended, within the meaning
                    of any regulations of any Regulatory Agency of European
                    countries listed in Exhibit B or any state or municipal law
                    in which the definition of adulteration and misbranding are
                    substantially identical to those contained in the United
                    States Federal Food, Drug and Cosmetic Act, or articles
                    which may not under the provisions of Sections 404 or 505 of
                    said Act be introduced into interstate commerce or which

                                       6
<PAGE>

                    may not under similar provisions of any foreign, state or
                    municipal law be introduced into commerce,

              (iii) manufactured or sold in violation of the federal Controlled
                    Substances Act, as amended, or any substantially similar
                    legislation of applicable European country (for the
                    countries set forth on Exhibit B) or state law,

              (iv)  manufactured or sold in violation of any of the provisions
                    of the Fair Labor Standards Act of 1938, as amended,

              (v)   manufactured or sold in violation of The Occupational Safety
                    and Health Act of 1970, as amended,

              (vi)  manufactured in violation of any applicable federal, state
                    or local environmental law or regulation, or

              (vii) manufactured in violation of any agreement (commercial or
                    otherwise), judgment, order or decree to which Mallinckrodt
                    is a party.

         (d)  Mallinckrodt certifies that neither it nor any of its affiliates
              nor any member of their staff has been disqualified or debarred by
              the FDA, or any other domestic regulatory authority, or any other
              applicable regulatory agency of any of the European countries set
              forth in Exhibit B for any purpose.

         (e)  Mallinckrodt warrants and represents that neither it nor any of
              its affiliates nor any member of their staff have been charged
              with or convicted under federal law, or other applicable laws of
              the European countries set forth in Exhibit B, for conduct
              relating to the development or approval, or otherwise relating to
              the regulation of any drug product under the Generic Drug
              Enforcement Act of 1992 or any other relevant statute, law or
              regulation.

         (f)  Mallinckrodt hereby represents and warrants that: Mallinckrodt has
              all rights and licenses necessary to manufacture and sell the
              Product to DAS.

         (g)  EXCEPT AS SET FORTH ABOVE IN THIS SECTION 8, MALLINCKRODT MAKES NO
              OTHER WARRANTY OR REPRESENTATION, EXPRESS OR IMPLIED, CONCERNING
              ITS PERFORMANCE HEREUNDER, INCLUDING ANY WARRANTY OF
              MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT
              TO "PRODUCT." UNDER NO CIRCUMSTANCES WILL MALLINCKRODT BE LIABLE
              HEREUNDER FOR CONSEQUENTIAL, INDIRECT, EXEMPLARY OR SPECIAL
              DAMAGES OF ANY KIND (INCLUDING, WITHOUT LIMITATION, LOST PROFITS),
              WHETHER OR NOT IN ANY PARTICULAR

                                       7
<PAGE>

          CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED
          AND FILED SEPARATELY WITH THE COMMISSION, CONFIDENTIAL TREATMENT
          HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

              CIRCUMSTANCE SUCH DAMAGES ARE FORESEEABLE AND WHETHER OR NOT
              MALLINCKRODT HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

    9.   FACILITY ACCESS.

         DAS, through its employees, consultants or other representatives will
         have the right during normal business hours and at a time mutually
         agreed to inspect Mallinckrodt's manufacturing operations to determine
         whether or not Mallinckrodt is complying in all respects with its
         obligations hereunder. DAS warrants that all such inspections and
         audits shall be carried out in a manner calculated not to unreasonably
         interfere with Mallinckrodt's conduct of business and to insure the
         continued confidentiality of Mallinckrodt's business and technical
         information. Further, DAS agrees to comply with all of Mallinckrodt's
         safety and security requirements during any visits to the Mallinckrodt
         facilities. Following an inspection which will in any way affect the
         production of Product for supply to DAS by the FDA or any other
         European Community authority (as set forth on Exhibit B), Mallinckrodt
         will notify DAS in writing of any material issues that may be pertinent
         to the supply of Product to DAS. The parties agree to cooperate in good
         faith and engage in an active dialogue in an effort to resolve any
         issues resulting from any such inspections.

    10.  FORCE MAJEURE.

         Neither party to this Supply Agreement shall be liable for or be in
         breach of any provision hereof for any failure or delay on its part to
         perform any obligation (other then the obligation to make payments when
         due) under any provision of this Supply Agreement because of an event
         of "force majeure," including, but not limited to, any act of God,
         fire, flood, explosion, unusually severe weather, war, insurrection,
         riot, sabotage, labor unrest, strikes or work stoppages or any other
         cause whatsoever, whether similar or dissimilar to those enumerated
         herein, beyond any reasonable possibility of control of such party, if
         and only if the party affected shall have used all reasonable efforts
         under the circumstances to avoid such occurrence and to remedy it
         promptly if it shall have occurred. If an event of force majeure
         causes a failure or delay in performance hereunder by Mallinckrodt
         for more than one hundred eighty (180) continuous days, DAS, at its
         option, may (i) terminate this Supply Agreement effective upon
         written notice to Mallinckrodt or (ii) may extend the delivery or
         performance period by the amount of time during which such delivery
         or performance was omitted or delayed.

    11.  RELATIONSHIP OF PARTIES.

         For all purposes hereof, Mallinckrodt shall be deemed to be an
         independent contractor and this Supply Agreement shall not create an
         agency, partnership, joint venture, or employer/employee relationship
         between DAS and Mallinckrodt, and nothing hereunder shall be deemed to
         authorize either party hereto to act for, represent or bind the other
         or any of its affiliates except as expressly provided in this Supply
         Agreement.

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION, CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       8
<PAGE>

    12.  CONFIDENTIALITY.

         (a)  DAS and Mallinckrodt shall maintain in confidence and not use or
              disclose to any third party, except as is specifically
              contemplated herein or is otherwise necessary to perform their
              respective obligations under this Supply Agreement, and then only
              on a confidential basis satisfactory to both parties, any
              information, including without limitation business and technical
              information, experience or data regarding any facility, programs,
              laboratories, processes, products, costs, equipment operation or
              customers, relating to the manufacture or sale of Product
              hereunder. The foregoing obligations of confidentiality and
              non-use shall survive the termination or expiration of this Supply
              Agreement for a period of five (5) years. Nothing herein shall
              prevent either party from disclosing any information required by
              statute or governmental regulations to be disclosed in a judicial
              or administrative proceeding, after the disclosing party has been
              given a reasonable opportunity, to the extent possible, to pursue
              all legal remedies for maintaining such information in confidence,
              or from using information which (i) has been published or has
              become part of the public domain other than by acts, omissions or
              fault of such party, (ii) was lawfully received by such party from
              a third party free of any obligation of confidence to such third
              party, (iii) or a party can demonstrate from its records was
              already in its possession prior to receipt thereof, directly or
              indirectly, from the other party. The party asserting the
              applicability of one of the exclusions from the obligation of
              confidentiality set forth in the immediately preceding sentence
              shall have the burden of proving the applicability of any such
              exclusion in any particular circumstance.

         (b)  Each party acknowledges that any breach by it of the
              confidentiality obligations set forth in this Section 12 would
              cause the other party irreparable harm for which compensation by
              monetary damages would be inadequate and, therefore, the party
              that has been harmed by any such breach shall have the right to an
              injunction or decree for specific performance, in addition to any
              other rights and remedies such party may have at law or in equity.

         (c)  Upon any termination of this Agreement, each recipient party will
              promptly return or destroy, at the discretion of the disclosing
              party, any confidential information of the disclosing party.

    13.  INDEMNIFICATION.

         (a)  Subject to the provisions of Section 8(g) hereof, Mallinckrodt (on
              behalf of itself and its affiliates) hereby agrees to indemnify,
              defend and hold harmless DAS and its affiliates from and against
              any and all demands, claims, actions, causes of action,
              assessments, losses, damages, injuries, liabilities, costs and
              expenses, including without limitation, interest, penalties and
              reasonable attorneys' fees and expenses (collectively

                                       9
<PAGE>

          CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED
          AND FILED SEPARATELY WITH THE COMMISSION, CONFIDENTIAL TREATMENT
          HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

              "Damages") asserted against, resulting to, imposed upon or
              incurred by DAS or its affiliates, directly or indirectly related
              to, arising out of or resulting from:

              (i)   any breach or failure of any of the representations,
                    warranties and covenants of Mallinckrodt contained herein,
                    including (without limitation) any breach or failure by
                    Mallinckrodt to perform any obligations contained herein,
                    and

              (ii)  any failure of Mallinckrodt to observe or comply in all
                    material respects with any laws, rules or regulations for
                    which and to the extent Mallinckrodt has promised compliance
                    hereunder.

         (b)  DAS hereby agrees to indemnify, defend and hold harmless
              Mallinckrodt and any of its affiliates from and against any and
              all Damages asserted against, resulting to, imposed upon or
              incurred by Mallinckrodt, directly or indirectly related to,
              arising out of or resulting from:

              (i)   any breach or failure of any of the representations,
                    warranties and covenants of DAS contained herein,

              (ii)  any failure of DAS to observe or comply in all material
                    respects with any laws, rules or regulations directly
                    related to DAS' performance hereunder, and

              (iii) DAS' or DAS' agents', distributors' or customers' use,
                    processing, transportation possession, disposal or sale of
                    any dosage Product manufactured by DAS, and whether used
                    alone or in combination with any other material.

         (c)  In the event of any claim being made against a party (the
              "Indemnified Party"), which triggers the indemnity obligations of
              the other party (the "Indemnifying Party") as set forth above,
              such indemnification shall be conditioned on compliance with the
              procedure outlined below. Provided that prompt notice is given of
              any claim or suit, the Indemnifying Party shall have the right to
              defend, contest, or otherwise protect against any such claim or
              suit, including by way of settlement and release, at its own
              expense and cost. The Indemnifying Party shall be entitled to sole
              control of the defense and settlement of any such claim or suit,
              and the Indemnified Party shall cooperate and provide such
              assistance as the Indemnifying Party may reasonably request in
              connection with the defense of the matter subject to
              indemnification.

    14.  TERM AND TERMINATION.

         (a)  Unless sooner terminated in accordance herewith, the initial
              term of this Supply Agreement shall be for a period commencing
              on June 9, 2000 and ending June 30, 2005, and shall
              automatically be renewed for additional one (1) year terms
              thereafter unless either party shall give written notice to the
              other, at least six (6) months prior to the end of the initial
              term or any renewal term, that it does not wish the Supply
              Agreement to be renewed for an additional one (1) year period.

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION, CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       10
<PAGE>

          CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED
          AND FILED SEPARATELY WITH THE COMMISSION, CONFIDENTIAL TREATMENT
          HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

         (b)  In addition to any other right of termination specifically
              provided for hereunder, this Supply Agreement may be terminated by
              either party for cause upon written notice to the other. For
              purposes of the preceding sentence, "cause" shall mean (without
              limitation):

              (i)   any material breach of this Agreement by a party which shall
                    go uncorrected for a period of thirty (30) days after
                    written notice of such breach has been given to the
                    defaulting party,

              (ii)  the institution by a party of voluntary proceedings in
                    bankruptcy or under any insolvency law or law for the relief
                    of debtors,

              (iii) the making by a party of an assignment for the benefit of
                    creditors or any dissolution or liquidation,

              (iv)  the filing of an involuntary petition under any bankruptcy
                    or insolvency law against a party, unless such petition is
                    dismissed or set aside within sixty (60) days from the of
                    its filing, or

              (v)   the appointment of a receiver or trustee for the assets or
                    business of a party, unless such appointment is dismissed or
                    set aside within sixty (60) days from the date of such
                    appointment.

         (c)  The representations and warranties of the parties hereunder,
              covenants which by their terms have effect after the termination
              or expiration hereof, and the parties' indemnification and
              confidentiality obligations shall survive termination or
              expiration of this Supply Agreement.

         (d)  In the event of any termination or expiration of this Supply
              Agreement, for any reason, Mallinckrodt shall (i) notwithstanding
              the effective date of any termination or the expiration, as the
              case may be, complete any orders for Product that were made by DAS
              and accepted by Mallinckrodt prior to such date, and DAS shall pay
              Mallinckrodt for any Product produced in accordance with such
              orders at the then applicable Product Price in effect on the
              effective date of termination hereunder or expiration (as the case
              may be). No less than thirty (30) days prior to the effective
              date of termination or expiration (as the case may be), DAS
              shall have the option to place an estimated order (+/- 20%) for
              all Product required for the twelve (12) month period following
              the effective date of termination or expiration (as the case
              may be) to be shipped according to Section 5c; provided that,
              Mallinckrodt shall not be required to accept all or any portion
              of such orders in the event this agreement has been terminated
              by Mallinckrodt pursuant to Section 14(b).

    15.  REMEDIES CUMULATIVE.

         The remedies provided in this Supply Agreement shall be cumulative and
         shall not preclude assertion by any party hereto of any other rights
         (whether legal or equitable in nature) or the seeking of any other
         remedies against party other party hereto.

[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION, CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       11
<PAGE>

    16.  BINDING EFFECT AND ASSIGNMENT.

         This Supply Agreement shall inure to the benefit of and be binding upon
         the parties hereto, their successors and assigns; provided, however,
         that neither party shall, without the prior written consent of the
         other party, assign or transfer any of its rights, benefits,
         obligations, or other interest under this Supply Agreement to any other
         party, except that, without seeking consent of the other party, either
         party may assign this Supply Agreement to any entity or person it
         controls, it is controlled by or is under common control with, or to
         any entity or person that acquires all or substantially all of its
         stock, assets or business or acquires that portion of its business to
         which this Supply Agreement relates, whether by merger, acquisition,
         sale or otherwise.

    17.  NOTICE.

         All notices, consents, approvals or other notifications required to be
         sent by one party to the other party hereunder shall be in writing and
         shall be deemed served upon the other party if delivered by hand or
         sent by United States registered or certified mail, postage prepaid,
         with return receipt requested, or by facsimile, or air courier,
         addressed to such other party at the address set out below, or the last
         address of such party as shall have been communicated to the other
         party. If a party changes its address, written notice shall be given
         promptly to the other party of the new address. Notice shall be deemed
         given on the day it is sent (in the case of delivery by method other
         than hand delivery) or the date of delivery (in the case of delivery by
         hand) in accordance with the provisions of this paragraph. The
         addresses for notices are as follows:

                  If to Mallinckrodt:

                           Mallinckrodt Inc.
                           c/o Pharmaceuticals Group
                           675 McDonnell Boulevard
                           Hazelwood, Missouri  63042
                           Attn:  Pat E. Cunningham
                                  Vice President Pharmaceuticals Group

                  with a copy to:

                           Mallinckrodt Inc.
                           675 McDonnell Boulevard
                           Hazelwood, Missouri  63042
                           Attn:  C. Stephen Kriegh
                                  Staff Vice President

                                       12
<PAGE>

                  If to DAS:

                           DrugAbuse Sciences
                           330 Distel Circle, Suite 150
                           Los Altos, CA  94022
                           Attn:  Philippe Pouletty,
                                  Chairman and Chief Executive Officer
                           Telephone:  (650) 417-2300
                           Fax:  (650) 417-2400

    18.  GOVERNING LAW AND JURISDICTION.

         This Agreement shall be governed by and construed in accordance with
         the substantive and procedural laws (as opposed to the conflicts of law
         provisions) of the State of New York.

    19.  WAIVER.

         The failure by any party to exercise any of its rights hereunder or to
         enforce any of the terms or conditions of this Supply Agreement on any
         occasion shall not constitute or be deemed a waiver of that party's
         rights thereafter to exercise any rights hereunder or to enforce each
         and every term and condition of this Supply Agreement.

    20.  MODIFICATIONS.

         This Supply Agreement may not be amended or modified except by a
         writing specifically referring to this Supply Agreement and executed by
         duly authorized representatives of both parties. The obligations of the
         parties are governed by the terms and conditions of this Supply
         Agreement and none of the general terms and conditions of any DAS
         purchase order or any Mallinckrodt acknowledgment or any substantially
         similar documents of either party will in any case be controlling or
         supersede the provisions hereof.

    21.  SEVERABILITY.

         A determination that any portion of this Supply Agreement is
         unenforceable or invalid shall not affect the enforceability or
         validity of any of the remaining portions hereof or of this Supply
         Agreement as a whole. In the event that any part of any of the
         covenants, sections or provisions herein may be determined by a court
         of law or equity to be overly broad or against applicable precedent or
         public policy, thereby making such covenants, sections or provisions
         invalid or unenforceable, the parties shall attempt to reach agreement
         with respect to a valid and enforceable substitute for the deleted
         provisions, which shall be as close in its intent and effect as
         possible to the deleted portions.

                                       13
<PAGE>

    22.  HEADINGS.

         The parties agree that the section and article headings are inserted
         only for ease of reference, shall not be construed as part of this
         Supply Agreement, and shall have no effect upon the construction or
         interpretation of any part hereof.

    23.  COUNTERPARTS.

         This Supply Agreement may be executed in several counterparts, and each
         executed counterpart shall be considered an original of this Supply
         Agreement.

    24.  ENTIRE AGREEMENT.

         This Supply Agreement represents the entire agreement and understanding
         of the parties hereto with respect to its subject matter and supersedes
         any and all prior agreements, understanding or discussions, whether
         written or oral, between the parties.

                                       14
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Supply
Agreement to be executed as of the day and year first above written.

                                        MALLINCKRODT INC.
DRUGABUSE SCIENCES, INC.                Pharmaceuticals Group

By:      /s/ Philippe Pouletty          By:      /s/ Pat E. Cunningham
   ----------------------------------      ---------------------------------
Name Printed:  Philippe Pouletty, M.D.     Pat E. Cunningham
Title Printed: Chairman and CEO            Vice President, Pharmaceuticals Group

Date:  June 8, 2000                        Date:  June 8, 2000

<PAGE>

                                    EXHIBIT A

                             PRODUCT SPECIFICATIONS

                            NALTREXONE BASE ANHYDROUS

<TABLE>
<S>                                        <C>       <C>      <C>     <C>
ITEM CODE:                                  [******]

FORMULA:                                    [******]

CAS REGISTRY No.:                           [******]

MOLECLLNIZ WEIGHT:                          [******]

APPEARANCE:                                 [******]

IDENTIFICATION:                             [******]

WATER CONTENT:                              [******]

TITRATION ASSAY:                            [******]

HEAVY METALS:                               [******]

RELATED SUBSTANCES:                         [******]

                                            [******] [******] [******] [******]

                                            [******]

HPLC ASSAY:                                 [******]

BIO-BURDEN/ENDOTOXIN LIMITS:

                                            DrugAbuse Sciences as part of our
                                            scale up and R&D efforts will be
                                            determining [******]. These limits
                                            will be based on the process and
                                            agreed upon by the parties at a
                                            later date.
</TABLE>

<PAGE>

                                    EXHIBIT B

                               EUROPEAN COUNTRIES

France
Germany
Italy
Netherlands
Norway
Portugal
Spain
Sweden
Switzerland
United Kingdom<PAGE>

                      SUPPLY AND MANUFACTURING AGREEMENT

         Agreement, dated as of July 20, 2000 (the "Effective Date"), by and
between DRUGABUSE SCIENCES, INC. ("DAS"), a California corporation with offices
at 330 Distel Circle, Suite 150, Los Altos, CA 94022, and EON LABS
MANUFACTURING, INC. ("Eon"), a Delaware corporation with offices at 227-15 North
Conduit Ave., Laurelton, NY 11413.

         The Parties hereby agree as follows:

                                 ARTICLE I

                                DEFINITIONS

         1.1 "AFFILIATE" shall mean (a) any corporation directly or indirectly
controlling, controlled by, or under common control with (to the extent of fifty
percent (50%) or more of its issued capital entitled to vote for the election of
directors) a Party or (b) any partnership, joint venture or other entity
directly or indirectly controlled by, controlling, or under common control with
(to the extent of fifty percent (50%) or more of voting power or otherwise
having power to control its general activities) a Party, but in each case only
for so long as such ownership or control shall continue.

         1.2 "AGREEMENT" shall mean this Supply and Manufacturing Agreement, as
amended from time to time.

         1.3 "DELIVERY DATE" shall mean a date for which delivery of Product is
requested in a Purchase Order.

         1.4 "FDA" shall mean the United States Food and Drug Administration.

         1.5 "LOT QUANTITY" or "LOT QUANTITIES" shall [******], or such other
amounts as the Parties may agree to in writing from time to time.

         1.6 "NET MARGIN" shall mean revenue actually received by DAS for
Product sold by DAS, less discounts, rebates, shelf adjustments, stock
adjustments, returns for credit and including the price paid to Eon for the
Product, and transportation cost for Product shipped to DAS's distribution
center/warehouse.

         1.7 "PARTY" shall mean either Eon or DAS; "PARTIES" shall mean Eon and
DAS.

         1.8 "PRODUCT" shall mean [******] hereunder by Eon that meet the
Specifications.

         1.9 "PURCHASE ORDER" shall mean a firm order for Product submitted by
DAS to Eon.

         1.10 "REGULATORY AUTHORITY" shall mean the FDA or such other agency or
instrumentality of the United States to which the responsibilities of the FDA
are given or delegated.

<PAGE>

         1.11 "PRODUCT ANDA" shall mean the Abbreviated New Drug Application
approval issued to Eon by the FDA and designated as ANDA #75-434 (as defined
below) for the Product, including any amendments or modifications thereto.

         1.12 "SPECIFICATIONS" shall mean the specifications for Product
manufactured and delivered by Eon as set forth in Exhibit I hereto (as such
Exhibit may be amended by the Parties from time to time). The "PACKAGING
SPECIFICATIONS" for the Product are set forth in Exhibit I-A.

         1.13 "TABLETS" shall mean [******].

         1.14 "TERM" shall have the meaning set forth in Section 6.1 hereof.

         1.15 "TERRITORY" shall mean the United States of America and its
territories and possessions.

                                  ARTICLE II

                          SALE AND PURCHASE OF PRODUCT

         2.1 SALE AND PURCHASE. Eon agrees to manufacture and supply DAS such
Lot Quantities of Product as DAS may order pursuant to and in accordance with
this Agreement, for DAS's use, distribution and sale; PROVIDED, HOWEVER, that
DAS may only distribute and sell Product to customers located in the Territory.

         2.2 PURCHASE ORDERS.

         (a) All purchases of Product hereunder shall be made by Purchase
Orders, and shall be subject to the terms of this Agreement. No additional terms
may be imposed by a Purchase Order.

         (b) Each Purchase Order shall include the total amount of Product
ordered in Lot Quantities with a [******] and the required Delivery Date, which
shall be no less than [******] after the receipt by Eon of such Purchase Order.
DAS may specify any proportion of [******] and [******] in a Purchase Order. Eon
will confirm receipt of each Purchase Order within [******] days of receipt.

         2.3 EXCLUSIVITY. During the Term, [******] and [******]; provided,
however, [******] (and only under) [******].

         2.4 TABLET TOOLING. Eon will, through its usual and customary sources
and subject to DAS's prior written approval given on a case-by-case basis and at
DAS's cost, order appropriate tooling that meets DAS's specifications for use in
the production of the Product (the "TOOLING"), provided that such specifications
comply with the requirements of the Product ANDA. Eon shall use the Tooling to
produce the Product and Eon shall only use the Tooling to produce Product to be
sold to DAS. Eon shall, at its cost, validate, use and maintain the Tooling

                                       2

<PAGE>

in accordance with its current standard operating procedures. Upon
termination of this Agreement, Eon shall, at DAS's option, either provide the
Tooling to DAS or destroy it.

         2.5 QUANTITY; FORECASTS. DAS shall deliver to Eon on a quarterly basis
during the Term a non-binding forecast of DAS quantity requirements for Product
for the following twelve (12) month period. Eon understands and agrees that DAS
forecasts are nonbinding until Purchase Orders are placed and that forecasts for
orders may be adjusted or cancelled by DAS in its sole discretion.

         2.6 MINIMUM PURCHASES. Subject to the terms and conditions of this
Agreement, DAS shall purchase a minimum of [******]. In the [******]. In each
[******] period thereafter during the Term, DAS [******].

         2.7 SHORTAGES. In the event there is inadequate [******] raw material
with which to manufacture all of the Product forecasted or ordered by DAS, Eon
shall immediately notify DAS of the shortfall and allocate the available supply
between DAS and Eon pro-rata based upon each Party's sales of Product over the
immediately preceding three (3) month period.

         2.8 MANUFACTURE/DELIVERY.

              (a) Eon shall manufacture the Product (i) according to the
Specifications, (ii) in compliance with all applicable FDA Good Manufacturing
Practices ("GMP"), the Federal Food, Drug, and Cosmetic Act (the "ACT"), and
all regulations promulgated under the Act, and (iii) in a GMP facility
inspected and approved by the applicable Regulatory Authority for the
manufacture of the Product. Eon shall provide DAS reasonable advance notice
before making any change to the Product manufacturing process that would
require notification to the FDA or any other Regulatory Authority. Eon will
inform DAS of any deviations from GMP procedures that may affect the quality,
potency or strength of the Product. If in the event that all or any of Eon's
GMP procedures that could effect the Product are or become the subject of an
investigation, inspection or other inquiry by a Regulatory Authority and such
investigation, inspection or inquiry results in the issuance of corrective
actions, warning letters or other notices (whether or not they require
immediate corrective action) related to GMP procedures for the Product, Eon
shall promptly inform DAS of such actions and provide DAS an opportunity to
review and consult with Eon regarding the situation and Eon's intended course
of action.

              (b) Eon shall package and label the Product in accordance with
the Packaging Specifications and the Product ANDA.

              (c) Eon shall ship Product in full Lot Quantities F.O.B. DAS's
designated facilities in accordance with DAS's instructions and no earlier
than three (3) days prior to the applicable Delivery Date, subject to the
commercial availability of the raw material [******]. DAS shall take title to
and risk of loss of each shipment of Product hereunder upon delivery to the
carrier of such shipment. For each lot of Product shipped to DAS, Eon will
send to DAS's offices copies of all applicable quality and testing records,
and any other documents reasonably required for DAS to demonstrate that the
Product conforms to all applicable Regulatory Authority requirements, which
shall be in a form reasonably acceptable to DAS. Eon shall prepay the freight
charges for each shipment of Product and add them to the appropriate invoice.

                                       3

<PAGE>

         2.9 REJECTION OF PRODUCT IN CASE OF NONCONFORMITY.

              (a) DAS may reject any portion of any Lot Quantities that (i)
does not fully conform to the Specifications or (ii) is adulterated or
misbranded within the meaning of the Federal Food, Drug and Cosmetic Act. In
order to reject a shipment, DAS must (i) give notice to Eon of DAS's intent
to reject the shipment within fifteen (15) business days (i.e., a day on
which DAS and Eon are each open for business) of receipt together with a
written indication of the reasons for such possible rejection, and (ii) as
promptly as reasonably possible thereafter provide Eon with notice of final
rejection and the full basis therefor; provided, however, that in the case of
Product having a latent defect that could not have been discovered upon
reasonable examination, DAS must only give notice of its intent to reject
within five (5) business days after discovery of such defects. Eon shall
notify DAS within thirty (30) days after receipt of a rejection notice from
DAS as to whether it accepts DAS's basis for such rejection.

              (b) DAS shall be entitled to a refund of the purchase price
(together with freight charges) of properly rejected Product at the time it
is ultimately rejected by DAS, provided that if Eon disputes the rejection,
refund shall be made, if at all, at the time the dispute is finally resolved
as set forth in Article IV. Eon shall notify DAS within thirty (30) days
whether it accepts DAS's basis for any rejection.

              (c) Whether or not Eon accepts DAS's basis for rejection,
promptly on receipt of a notice of rejection, Eon shall use all diligent
efforts, at DAS's request, to provide replacement Product within sixty (60)
days after receipt of a rejection notice from DAS.

              (d) DAS shall return rejected Product to Eon at Eon's cost.

         2.10 STABILITY STUDIES AND RELATED TESTING. It is DAS's intention to
develop [******] for Product. In support of DAS, and at DAS's request, Eon shall
perform all applicable tests, release testing, and stability studies for the
Product for [******] specifications developed by DAS in accordance with the Eon
ANDA, as more specifically set forth in Exhibit III. DAS shall [******]
conducting such studies on [******].

                                  ARTICLE III

                                QUALITY DISPUTES

         3.1 PRODUCT QUALITY DISPUTES. If DAS rejects any Product and if the
Parties have not agreed mutually on a remedy, the Parties shall timely consult
with each other and attempt to resolve the discrepancies. If the Parties cannot
resolve the discrepancies in a timely manner, they shall promptly nominate an
independent, reputable laboratory, which shall carry out analyses with respect
to such Product as may be jointly agreed upon by Eon and DAS and at the Parties'
joint expense. The results obtained by the laboratory shall be binding on the
Parties for purposes of this Agreement.

         If the results conclude that the Product conformed to the
Specifications, DAS shall reimburse Eon amounts paid to the testing laboratory.
If the results conclude that the Product does not conform to the Specifications,
Eon shall reimburse DAS amounts paid to the

                                       4

<PAGE>

laboratory. In the event the laboratory cannot conclude whether the Product
conforms or not to the Specifications, the Parties shall equally share the
laboratory expenses.

         3.2 NONPAYMENT FOR NONCONFORMING PRODUCT. If DAS rejects any Product
and the laboratory determines that such Product does not conform with the
Specifications, Eon shall at DAS's option either replace the nonconforming
Product as soon as reasonably possible (but no later than sixty (60) days) or
issue a refund therefor. In the event of refunds, the purchase price of such
Product (along with other applicable costs such as insurance and freight
charges) shall be promptly refunded to DAS.

                                  ARTICLE IV

                               PRICE AND PAYMENTS

         4.1 PRICE/PAYMENTS. DAS shall pay Eon the amounts set forth in Exhibit
II hereto for Product delivered by Eon pursuant to this Agreement. In addition,
DAS shall pay Eon the sum of One Hundred Fifty Thousand Dollars, which shall
be paid as follows: (a) Seventy-Five Thousand Dollars ($75,000) within thirty
days of the Effective Date and (b) Seventy-Five Thousand Dollars ($75,000)
within thirty (30) days of receipt by DAS of the first Lot Quantity delivered
hereunder.

         4.2 METHOD OF PAYMENT. All payments for Product delivered to DAS by Eon
hereunder shall be [******] therefor.

         4.3 ROYALTIES. [******]. Beginning [******] after DAS has sold the
first Product, [******] (each a "Period"): (a) [******]; (b) [******], and (c)
[******] during such Period. [******] of the end of the [******] (each, a
[******].

         4.4 REPORTING AND ACCESS.

              (a) Within sixty (60) days after the end of each Quarter, DAS
shall provide Eon with reports indicating the total number of Tablets sold
during such Quarter, and reasonably detailed calculations of the
corresponding Net Margin. Such reports shall be subject to Eon's audit and
approval.

              (b) No more than once in any twelve (12) month period during
the term and for one (1) year thereafter, Eon shall be entitled to appoint an
independent auditor bound to confidentiality to audit, during regular
business hours and upon reasonable prior notice, DAS's relevant books and
records for the purpose of verifying the accuracy of the calculations of Net
Margin provided pursuant to Section 4.4(a) hereof. Eon shall bear the cost
and expense of any such audit, unless such audit shows underpayment by DAS by
more than five percent (5%), in which case DAS will bear the cost and expense
of such audit.

                                   ARTICLE V

                        QUALITY ASSURANCE/SAFETY/RECALLS

         5.1 QUALITY CONTROL. Eon agrees to keep DAS reasonably informed on
Product quality control and any other issues concerning the Product or the
manufacture thereof. The parties agree to discuss in good faith the appropriate
course of action with respect to any such

                                       5

<PAGE>

issues. In the event of an inspection by the FDA or any other Regulatory
Authority that relates to the Product or the manufacture thereof, Eon shall
notify DAS within twenty (20) business days in writing of the details and
results of any such investigation.

         5.2 SAFETY/REGULATORY MATTERS. DAS shall give Eon notice within five
(5) business days of any complaints it receives regarding the Product. Eon shall
give DAS notice as described below of any confirmed complaints or other
information it receives regarding the safety of the Product, including any
information on adverse, serious or unexpected events associated with the use of
the Product. However, for serious, unexpected events, notice must be given by
telephone and fax to the appropriate representative of the other party
immediately after receipt of the information and followed by written notice not
more than one business day thereafter. Eon shall promptly inform DAS of any
environmental non-compliance or regulatory issues that could jeopardize Eon's
ability to manufacture, package and supply the Product hereunder. Eon shall
inform DAS's Vice President of Regulatory Affairs via telephone and fax within
two business days of receipt of any communication from the FDA or other
Regulatory Authority regarding the Product and will promptly furnish DAS with
copies of any such communication (including any notice, form, warning, report or
claim). Eon is responsible for reporting all adverse events to the appropriate
Regulatory Authority. Eon shall notify DAS prior to making any changes to the
Product label.

         5.3 RECALLS. If DAS reasonably decides to or is required to initiate a
Product recall, withdrawal or field correction with respect to, or if there is
any governmental seizure of, any Product supplied hereunder (collectively
"RECALL"), DAS shall notify Eon promptly of the details regarding such Recall,
and provide copies of all relevant documentation concerning such Recall. Eon
shall cooperate with and use all reasonable efforts to assist DAS in
investigating any such Recall. DAS will be responsible for coordinating any such
Recall, including providing appropriate notice to DAS's customers. All
regulatory contacts that are made and all other activities concerning seizure,
recall, withdrawal or field correction shall be coordinated by Eon in
consultation with DAS. If any such Recall arises substantially out of any act,
omission or fault of Eon (or its representatives or agents), Eon shall replace
all recalled Product on a timely basis at no cost or charge to DAS.

         5.4 INSURANCE. DAS agrees to maintain, throughout the term of this
Agreement for so long as it is commercially reasonable, [******] with a minimum
[******]. Eon agrees to maintain, throughout the term of this Agreement for so
long as it is commercially reasonable, [******] with a minimum of [******].

                                   ARTICLE VI

              TERMINATION, RIGHTS AND OBLIGATIONS UPON TERMINATION

         6.1 TERM. Unless otherwise terminated pursuant to Section 6.2
hereof, this Agreement shall begin on the Effective Date and continue in
effect thereafter for a period of five (5) years from the date Effective
Date. Thereafter this Agreement shall automatically renew for additional two
(2) years periods unless either Party gives written notice of intent to
terminate not less than one (1) year prior to the expiration of the then
current term (the initial term and any renewal terms shall be referred to
collectively as the "TERM").

                                       6

<PAGE>

         6.2 TERMINATION. This Agreement may be terminated in its entirety by
either Party immediately upon the occurrence of any of the following events:

              (a) if the other Party entirely ceases to do business, or
otherwise completely terminates its business operations;

              (b) if the other Party breaches any material provision of this
Agreement and fails to cure such breach within sixty (60) days of receipt of
written notice describing such breach.

         6.3 RIGHTS AND OBLIGATIONS ON EXPIRATION OR TERMINATION. Except to the
extent expressly provided to the contrary, the following provisions shall
survive the termination of this Agreement: ARTICLE III, ARTICLE IV, ARTICLE V,
this Section 6.3, ARTICLE VII, ARTICLE VIII, and ARTICLE IX. Any rights of Eon
to payments accrued through the termination of this Agreement as well as
obligations of the Parties under firm orders for purchase and delivery of
Product at the time of such termination shall remain in effect, except that in
the case of termination under Section 6.2 hereof, the terminating Party may
elect whether obligations under firm orders shall remain in effect.

                                ARTICLE VII

                  COVENANTS; REPRESENTATIONS AND WARRANTIES;
                   INDEMNIFICATION; LIMITATION ON LIABILITY

         7.1 COVENANTS.

              (a) DAS covenants and agrees that:

                   (i) It will promote the sale and distribution of the
Product in a manner consistent with that employed by DAS in its promotion of
other products of similar character, and shall use diligent efforts to
facilitate the initiation of the sale of the Product;

                   (ii) During the Term it will not [******]; and

                   (iii) It will comply with all applicable local, state or
federal rules, regulations, statutes and laws (collectively, "LAWS") in
promoting, marketing, distributing and selling the Product.

              (b) Eon covenants and agrees that:

                   (i) All Product shall, [******] after the date of delivery
of such Lot Quantity to DAS (i.e., that Product performance/potency/efficacy
during the entire shelf life period shall comply with the Specifications);

                                       7

<PAGE>

                   (ii) Product shall be registered with the State Boards of
Pharmacy in all states, territories and possessions of the United States
where such registration is required to market the Product, within six months
of the Effective Date;

                   (iii) The Product will be manufactured, packaged, stored
and shipped in conformance with all applicable GMP's;

                   (iv) The Product will be manufactured, packaged and stored
in facilities which are approved by the FDA at the time of such manufacture,
packaging and storage, to the extent such approval is required by Law;

                   (v) Eon has obtained and will maintain and comply with all
licenses, permits and approvals of applicable governmental agencies as may be
required for Eon's facility and to manufacture, package, store and ship the
Product; and

                   (vi) Eon will have sole responsibility for adopting and
enforcing safety procedures for the manufacture, packaging, storage, and
shipment of Product at Eon's facility.

         7.2 REPRESENTATIONS AND WARRANTIES.

              (a) Eon hereby represents and warrants that: (i) the
manufacture, use and/or sale of the Product does not infringe any patent,
trademark, trade secret or other intellectual property or proprietary right
of any third party; (ii) it has full authority to enter into this Agreement
and has all rights and licenses necessary to manufacture and sell the Product
to DAS; (iii) there is nothing contained in any other agreements to which Eon
is a party which prohibits or restricts Eon from entering into this
Agreement; (iv) Eon is licensed to sell the Product in all states,
territories and possessions of the United States where licensure is required
for sale; and (v) Eon shall maintain the Product ANDA in accordance with all
applicable laws and regulations.

              (b) DAS hereby represents and warrants that: (i) it has full
authority to enter into this Agreement and has all rights and licenses
necessary to market, distribute and sell the Product; and (iii) there is
nothing contained in any other agreements to which DAS is a party which
prohibits or restricts DAS from entering into this Agreement.

         7.3 INDEMNIFICATION.

              (a) Each Party hereby [******].

              (b) The foregoing indemnity obligations are conditioned upon
the Indemnified Party providing the Indemnifying Party (a) prompt notice of
any claim, proceeding or suit, (b) sole control of the defense and settlement
of any such claim, proceeding or suit, and (c) reasonable cooperation, at the
Indemnifying Party's expense, in connection with the defense of the matter
subject to indemnification. The Indemnifying Party shall keep the Indemnified
Party fully informed as to the progress of the defense and any proposed
settlement, and the Indemnifying Party shall furnish the Indemnified Party
with copies of all litigation and settlement papers in connection therewith.
The Indemnified Party shall have the right to

                                       8

<PAGE>

participate (subject to the control of the Indemnifying Party), at its own
cost and expense and through counsel selected by it, and subject to court
approval, in the defense of any such claim.

         7.4 LIMITATION ON LIABILITY. EXCEPT FOR EITHER PARTY'S INDEMNIFICATION
OBLIGATIONS AS SET FORTH ABOVE, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE
OTHER FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES ARISING IN
ANY WAY OUT OF THIS AGREEMENT.

                                  ARTICLE VIII

                             PROPRIETARY INFORMATION

         8.1 Each Party agrees that it (i) shall treat and maintain as
confidential, (ii) shall not use (except as contemplated by this Agreement and
then only on a confidential basis), and (iii) shall not disclose, in whole or in
part, to any third party (other than such Party's agents, officers, employees
and consultants (collectively, "REPRESENTATIVES") to whom disclosure is
permitted under paragraph 8.2) any information received from the other Party in
connection with this Agreement that is marked or identified as confidential or
proprietary information at or before the time of disclosure (all such
information being hereinafter referred to as "PROPRIETARY INFORMATION").

         8.2 The provisions of Section 8.1 shall not apply to any Proprietary
Information which the receiving Party can show (i) was in the public domain at
the time of its receipt, (ii) is published or otherwise becomes, after its
receipt thereof, a part of the public domain other than by reason of any of the
receiving Party's acts or omissions (but only after, and only to the extent
that, it is published or otherwise becomes part of the public domain), (iii) has
been put in the receiving Party's possession or knowledge (as evidenced by
written records), prior to the time of its receipt thereof from the other Party,
by any third party or by employees of the receiving Party (acting directly or
indirectly for or on its behalf) as a matter of right and without restriction on
use or disclosure, (iv) was in the receiving Party's possession or knowledge (as
evidenced by written records) prior to the date of this Agreement, (v) is
developed by the receiving party independently of any disclosure received by the
disclosing party, as evidenced by contemporaneous written records, or (vi) is
required to be disclosed by the receiving Party pursuant to FDA regulations, law
or judicial order, provided that, in such event, the receiving party shall
notify the disclosing party promptly so that the disclosing party may seek a
protective order.

         8.3 The Parties shall restrict the Proprietary Information to their
Representatives who are directly involved in the performance of this Agreement
to the extent that they have need of such, and then only on a confidential
basis. The receiving party shall be responsible for the breach of this ARTICLE
VIII by it or any of its Representatives.

         8.4 The Parties acknowledge and agree that damages from a material
breach of this ARTICLE VIII shall be difficult or impossible to ascertain, and
further agrees that the other Party may therefore enforce the provisions of this
ARTICLE VIII by seeking preliminary and/or permanent injunctive relief.

                                       9

<PAGE>

                                   ARTICLE IX

                                  MISCELLANEOUS

         9.1 FORCE MAJEURE. No failure or omission by a Party in the performance
of any obligation under this Agreement shall be deemed a breach of this
Agreement or create any liability if such failure or omission shall arise from
any cause or causes beyond the reasonable control of such Party which cannot be
overcome through due diligence, including, but not limited to, strikes, riots,
war, acts of God, invasion, fire, explosion, floods, delay of carrier,
unexpected shortage or failure in the supply of raw materials, energy shortage
and acts of government or governmental agencies or instrumentalities. The Party
affected by any such event shall keep the other Party informed of the status
thereof and shall use diligent efforts to overcome such event.

         9.2 ENTIRE AGREEMENT. This Agreement contains the entire agreement of
the Parties regarding the subject matter hereof and supersedes all prior
agreements, understandings and negotiations regarding the same. This Agreement
may not be changed, modified, amended or supplemented except by a written
instrument signed by both Parties.

         9.3 ASSIGNABILITY. This Agreement may not be assigned by either Party
without the prior consent of the other Party (and any attempt to do so shall be
void); provided, however, that either Party may assign this Agreement to any
entity that acquires substantially all of its stock, assets or business.

         9.4 SEVERABILITY. If any provision of this Agreement shall be held
illegal or unenforceable, that provision shall be limited or eliminated to the
minimum extent necessary so that this Agreement shall otherwise remain in full
force and effect and enforceable.

         9.5 FURTHER ASSURANCES. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts as may be
necessary or appropriate to carry out the purposes and intent of this Agreement.

         9.6 NOTICE AND REPORTS. All notices and other communications hereunder
and all legal process in regard hereto shall be validly given, made or served if
in writing, (i) on the date delivered, if delivered personally (by courier
service or otherwise) or via confirmed facsimile, (ii) on the business day after
the date sent, if sent by nationally recognized overnight courier service using
its highest priority service, or (iii) four (4) days after the date sent, if
mailed by first-class registered mail, postage-prepaid and return receipt
requested, to the address of the Party to receive such notice or other
communication set forth below, or at such other address as any Party may from
time to time advise the other Party pursuant to this Section 9.6:

           To Eon:                   Eon Labs Manufacturing, Inc.
                                     Attn: Chief Executive Officer:
                                     227-15 North Conduit Avenue
                                     Laurelton, NY 11413
                                     Tel: (718) 276-8699
                                     Fax: (718) 949-3120

                                       10

<PAGE>

           To DAS:                   DrugAbuse Sciences, Inc.
                                     Attn:  Chief Executive Officer
                                     330 Distel Circle, Suite 150
                                     Los Altos, CA  94022
                                     Tel:  (650) 417-2300
                                     Fax:  (650) 417-2400

         9.7 RELATIONSHIPS OF THE PARTIES. The relationship between the Parties
is that of independent contractors. Neither Party is an agent, partner or
employee of the other Party and neither Party has any right or any other
authority to enter into any contract or undertaking in the name of or for the
account of the other Party or to assume or create any obligation of any kind,
express or implied, on behalf of the other Party, nor will the act or omissions
of either create any liability for the other Party. The Agreement shall in no
way constitute or give rise to a partnership between the Parties.

         9.8 WAIVER. The waiver by either Party of a breach of any provisions
contained herein must be in writing and shall in no way be construed as a waiver
of any subsequent breach of such provision or the waiver of the provision
itself.

         9.9 GOVERNING LAW. This Agreement shall be governed by and construed
pursuant to the laws of the State of New York, without regard to conflict of
laws provisions thereof.

         9.10 CAPTIONS. Paragraph captions are for convenience only and in no
way are to be construed to define, limit or affect the construction or
interpretation hereof.

         9.11 COUNTERPARTS. This Agreement may be executed in counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

         IN WITNESS WHEREOF, the Parties have executed this Agreement to be
effective as of the date first written above.

                                 Eon Labs Manufacturing, Inc.

                                 By:    /s/ Frank Dellafera  7/25/00
                                    ---------------------------------------
                                 Title: V.P. Sales & Marketing
                                       ------------------------------------

                                 DrugAbuse Sciences, Inc.

                                 By:    /s/ Elizabeth Greetham  7/31/00
                                    ---------------------------------------
                                 Title: CFO and Sr. VP Business Development
                                       ------------------------------------

                                       11

<PAGE>

                                    EXHIBIT I

                             PRODUCT SPECIFICATIONS

A.       TABLETS

         Tablets shall be produced utilizing [******].

B.       PRODUCT SPECIFICATIONS

         All Product supplied by Eon will meet all applicable specifications
         approved by the FDA or other Regulatory Authority and will continue to
         meet such specifications up through the Product expiration date.

<PAGE>

                                  EXHIBIT I-A

                            PACKAGING SPECIFICATIONS

The Product shall be packaged and labeled in accordance with mutually agreed
upon specifications and Eon's ANDA in [******] Tablets. The [******] a child
resistant closure.

<PAGE>

                                   EXHIBIT II

                                     PRICING

The sales price to DAS will be Eon's [******] as calculated following Generally
Accepted Accounting Principles [******]. Generally Accepted Accounting
Principles utilized are to be consistent with those used internally by Eon to
determine cost of their other products.

As the date of signing this contract Eon's cost and DAS's purchase price are as
follows:

<TABLE>
<CAPTION>
                                                                                DAS
                                            EON'S COST                   PURCHASE PRICE
<S>                                         <C>                          <C>
         Bottles of 30 tablets                   $ [******]                     $ [******]

         Bottles of 100 tablets                  $ [******]                     $ [******]
</TABLE>

DAS's purchase price [******] may be added to DAS's purchase price.

The [******], when Eon performs [******]. Except in conjunction with a general
updating of its standards, Eon will not be required to [******]. DAS will be
notified of the [******].

Eon's cost and DAS's purchase price will be [******].

Cost of the Product as determined under Generally Accepted Accounting Principals
include [******]. Indirect costs include but are not limited to [******], etc.

Costs from the following departments are to be excluded in determining Eon's
cost of the Product:  [******].

Eon will permit DAS duly authorized certified public account, to whom Eon has no
reasonable objection to inspect the books and records of Eon for up to two prior
years at reasonable times during regular business hours for the purpose of
verifying Eon's cost of the Product. Such accountants shall treat any
information obtained from Eon as confidential and will disclose to DAS only
whether Eon's costs have been verified.

In the event that the certified public accountant engaged by DAS and Eon do not
agree on the cost of the Product, a mutually agreed upon certified public
accountant will be engaged. The decision of the mutually agreed upon certified
public accountant will be binding on both parties. The cost of the mutually
agreed upon certified public accountant will be shared equally regardless of
their decision.

<PAGE>

                                   EXHIBIT III

                                   CMC STUDIES

Eon shall be responsible for receiving FDA approval of Product produced or
packaged with any new tooling or packaging formats. Eon will be responsible for
conducting all [******]. In the event that DAS would like to introduce an
[******], Eon will be responsible for conducting any [******].

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]